SCHEMBL2687569

SCHEMBL2687569

c1csc(-c2nc3cc(-c4nc5ccccc5o4)ccc3n2C2CCOCC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.40
ALDH1A1 P00352 8/20 0.39
HPGD P15428 6/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
GPR119 Q8TDV5 3/20 0.39
HSPD1 P10809 1/20 0.38
PTPN5 P54829 1/20 0.38
HSPE1 P61604 1/20 0.38
KDM4E B2RXH2 9/20 0.37
MAPT P10636 4/20 0.37
NPC1 O15118 6/20 0.37
RAB9A P51151 5/20 0.37
SMN1; SMN2 Q16637 5/20 0.37
NFKB1 P19838 2/20 0.37
STAT1 P42224 2/20 0.37
NFKB2 Q00653 2/20 0.37
RELA Q04206 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2688404 0.86 MET (0.43) METALDH1A1HPGDMEN1KMT2A
SCHEMBL2688587 0.85 CYP11B2 (0.42) METALDH1A1HPGDMEN1KMT2A
SCHEMBL2686059 0.83 OPRM1 (0.43) METALDH1A1HPGDHSPD1PTPN5
SCHEMBL2688684 0.83 MET (0.44) METALDH1A1HPGDMEN1KMT2A
SCHEMBL15693825 0.83 BCAT2 (0.34) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL10219917 0.83 MET (0.43) METALDH1A1HPGDHSPD1PTPN5
SCHEMBL2687495 0.82 ALOX5 (0.46) METALDH1A1HPGDMEN1KMT2A
SCHEMBL2686061 0.82 NPC1 (0.47) METALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL2686461 0.82 MET (0.41) METALDH1A1HPGDMEN1KMT2A
SCHEMBL2687450 0.82 MET (0.42) METALDH1A1HPGDKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
EP-2436683-B1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL CO (JP) 2014-05-14 EP disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed
WO-2010137349-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS 住友化学株式会社 (JP) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 MET 41/4885ALDH1A1 1772/4885HPGD 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.